Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology.

[1]  G R Taylor,et al.  Diagnosis of copy number variation by Illumina next generation sequencing is comparable in performance to oligonucleotide array comparative genomic hybridisation. , 2013, Genomics.

[2]  Rashmi Kanagal-Shamanna,et al.  Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.

[3]  Seung-Yong Jeong,et al.  Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing , 2013, PloS one.

[4]  J. Lee,et al.  P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy , 2013, Oncotarget.

[5]  M. Odenthal,et al.  Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues , 2013, Journal of Clinical Pathology.

[6]  Yu-ping Wang,et al.  Comparative Studies of Copy Number Variation Detection Methods for Next-Generation Sequencing Technologies , 2013, PloS one.

[7]  Ashish Choudhary,et al.  Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.

[8]  J. Leamon,et al.  Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. , 2013, The Journal of molecular diagnostics : JMD.

[9]  A. Antón,et al.  Advanced HER2-positive gastric cancer: current and future targeted therapies. , 2013, Critical reviews in oncology/hematology.

[10]  B. Neyns,et al.  Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. , 2012, International journal of oncology.

[11]  John D Pfeifer,et al.  Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia , 2012, Modern Pathology.

[12]  T. Hudson,et al.  The Genetic Basis for Cancer Treatment Decisions , 2012, Cell.

[13]  E. Wall,et al.  Current technologies for HER2 testing in breast cancer. , 2011, Critical reviews in oncology/hematology.

[14]  G. Tse,et al.  Epidermal growth factor receptor gene amplification and protein overexpression in basal‐like carcinoma of the breast , 2011, Histopathology.

[15]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[16]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[17]  R. Osamura,et al.  Evaluation of HER2 gene amplification in invasive breast cancer using a dual‐color chromogenic in situ hybridization (dual CISH) , 2010, Pathology international.

[18]  K. Maclennan,et al.  Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens , 2010, Nucleic acids research.

[19]  Paul Medvedev,et al.  Computational methods for discovering structural variation with next-generation sequencing , 2009, Nature Methods.

[20]  L. Campbell,et al.  Gene amplification in myeloid leukemias elucidated by fluorescence in situ hybridization. , 2009, Cancer genetics and cytogenetics.

[21]  A. Kaye,et al.  The EGFRvIII variant in glioblastoma multiforme , 2009, Journal of Clinical Neuroscience.

[22]  Paul J. van Diest,et al.  HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization , 2008, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[23]  A. Jimeno,et al.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[25]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[26]  J. Isola,et al.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Cameron,et al.  Amplification of the ABL gene in T-cell acute lymphoblastic leukemia , 2004, Leukemia.

[29]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[30]  A. Hagemeijer,et al.  MLL amplification in myeloid leukemias: A study of 14 cases with multiple copies of 11q23 , 2000, Genes, chromosomes & cancer.

[31]  Teri A. Crosby,et al.  How to Detect and Handle Outliers , 1993 .